New research published in May indicates a possible connection between B cells and the occurrence of systemic lupus erythematosus symptoms.
Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis
NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…
Data Collection Drives Evaluation of Psoriasis Treatments
For six years, the Psoriasis Longitudinal Assessment and Registry (PSOLAR) has collected data to assess the infection risk for drugs treating systemic psoriasis.
Many U.S. Hospitals Mark Up Prices 1,000%
NEW YORK (Reuters)—Even the astronomical price markups that consumers regularly pay for, say, wine in restaurants pale beside those in some U.S. hospitals: The price for procedures is often 10 times the cost, according to a study published Monday in the journal Health Affairs. Of the 50 hospitals with the highest markups, 49 are for-profit,…
Medical Data, Cybercriminals’ Holy Grail, Now Espionage Target
SINGAPORE (Reuters)—Whoever was behind the latest theft of personal data from U.S. government computers, they appear to be following a new trend set by cybercriminals: targeting increasingly valuable medical records and personnel files. This data, experts say, is worth a lot more to cybercriminals than, say, credit card information. And the Office of Personnel Management…
U.S. NIH Drug Facility Suspended after Contamination Found
(Reuters)—The National Institutes of Health said on Thursday it had suspended operations of a facility that makes products used for clinical research after the discovery of fungal contamination in two vials of albumin. Vials made from the same batch of albumin had been administered to six patients, though it is not known if those were…
Biologic Drugs for Psoriasis Are Rarely Stopped for AEs
NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…
Clinical Trials Ongoing for Brodalumab
Brodalumab, an interleukin (IL) 17 inhibitor, is currently in early clinical trials (Phase 1b and Phase 2) for a number of different autoimmune diseases.1 Amgen recently terminated its co-development and commercialization agreement with AstraZeneca for the brodalumab investigational program in trials for moderate to severe plaque psoriasis, psoriatic arthritis and axial spondyloarthritis. Amgen’s decision to…
Weight Loss May Predict Early Death in RA Patients
According to a new study, patients with RA experiencing weight loss unrelated to exercise may be at risk of premature death.
Medicare Paid Doctors $90 Billion in 2013, up 17%
NEW YORK (Reuters)—Medicare, the government-run health insurance program for elderly and disabled Americans, paid physicians $90 billion in 2013, up 17% from $77 billion in 2012, U.S. healthcare officials reported on Monday. Physician payments accounted for less than one-fifth of Medicare’s 2013 net outlays of $492 billion, which rose from $466 billion in 2012. Payments to…
- « Previous Page
- 1
- …
- 585
- 586
- 587
- 588
- 589
- …
- 818
- Next Page »